Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma.
Blood
; 140(19): 2024-2036, 2022 11 10.
Article
in En
| MEDLINE
| ID: mdl-35914220
Full text:
1
Database:
MEDLINE
Main subject:
Lymphoma, Large B-Cell, Diffuse
/
Receptors, Chimeric Antigen
Type of study:
Health_economic_evaluation
Limits:
Adult
/
Aged
/
Humans
Country/Region as subject:
America do norte
Language:
En
Journal:
Blood
Year:
2022
Type:
Article
Affiliation country:
Canada